GlassScriptPhysician profile
Kenneth L Thomas
NPI 1881699015
$5,559.83
in general payments reported to CMS, 2019-2025
33 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $887 · 2021: $940 · 2022: $987 · 2023: $967 · 2024: $391 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,204.84 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,030.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $561.07 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $460.11 | 2019-2025 | Evenity, Repatha, Repatha |
| Abbvie INC. | $317.66 | 2021-2024 | Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $228.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.38 | 2019-2022 | |
| Astellas Pharma US INC | $154.69 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $150.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $148.73 | 2019-2023 | Verquvo, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $142.69 | 2019-2021 | |
| Abbott Laboratories | $119.60 | 2021-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $98.74 | 2020-2025 | Nexletol |
| Pfizer INC. | $85.10 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $77.58 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $61.84 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $48.78 | 2023-2024 | Sunosi, Auvelity |
| Allergan, INC. | $46.52 | 2019 | |
| Idorsia Pharmaceuticals US INC | $44.35 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $44.23 | 2019-2020 | |
| Amarin Pharma, INC. | $43.69 | 2019-2020 | |
| Intuitive Surgical, INC. | $38.89 | 2023 | Da Vinci Surgical System |
| Supernus Pharmaceuticals, INC. | $38.23 | 2023-2024 | Qelbree, Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $37.32 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $34.91 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $30.57 | 2021-2022 | |
| Eisai INC. | $28.47 | 2020 | |
| Depuy Synthes Sales INC. | $25.88 | 2025 | Na |
| Shire North American Group INC | $23.41 | 2019 | |
| International Rehabilitative Sciences, INC | $23.24 | 2023 | Rs 4i Plus Sequential Stimulator |
| Biohaven Pharmaceutical Holding Company LTD. | $18.28 | 2022 | |
| Daiichi Sankyo INC. | $15.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.